Low Testosterone: Symptoms, Causes & Options | PeptideWorld

Low Testosterone: Symptoms, Causes & Options

🧬 Hormone Health ⏱ 12 min read 🎓 Beginner
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. A diagnosis of testosterone deficiency requires clinical evaluation and laboratory testing by a licensed healthcare provider. Do not self-diagnose or self-treat.

Low testosterone is more common than most men realise — and more nuanced than a single blood test can capture. The clinical reality is that testosterone levels exist on a spectrum, that symptoms overlap significantly with other conditions, and that the right course of action depends heavily on what is causing the decline. Many men with low numbers have no symptoms; many men with symptoms have normal numbers. Understanding both is essential before any treatment decision is made.

This guide covers what low testosterone is, how common it genuinely is, what causes it, how it is properly diagnosed, and what the full range of management options looks like — from lifestyle changes through to TRT.

Key Takeaways

  • Testosterone deficiency requires BOTH low testosterone levels AND associated symptoms — biochemical evidence alone is not sufficient for diagnosis. This is the position of the AUA, Endocrine Society, and ICSM 2024 consensus panel.
  • The most symptom-specific indicators of true testosterone deficiency are sexual symptoms: reduced libido, reduced morning erections, and erectile dysfunction. Non-sexual symptoms (fatigue, mood changes) are too non-specific for confident attribution to testosterone alone.
  • Prevalence varies widely by criteria used — from ~2% of men (strict: low T + sexual symptoms) to ~39% of men over 45 (broader biochemical criteria). The true clinically significant rate is much lower than marketing suggests.
  • The most common reversible causes — obesity, sleep apnoea, opioid use, and chronic stress — should be addressed and reassessed before TRT is initiated. Weight loss alone can normalise testosterone in obese men.
  • Two morning testosterone tests are required for diagnosis. A single result below 300 ng/dL is not sufficient for diagnosis — the result must be confirmed on a separate occasion.
  • The 5th International Consultation on Sexual Medicine (ICSM 2024) published comprehensive guidance — the most current expert consensus on diagnosis and management of male hypogonadism available.

How Common Is Low Testosterone?

The answer depends entirely on which definition is being used — a point of significant clinical and commercial confusion. Very different prevalence figures emerge from different methodological approaches, and this ambiguity has been exploited by direct-to-consumer marketing to overstate how many men "have low T."

~2%
Men with symptomatic testosterone deficiency using strict criteria (low T + specific sexual symptoms)
19%
Men over 60 with low testosterone — Baltimore Longitudinal Study on Ageing
5–35%
Estimated proportion of hypogonadal men who actually receive treatment for their condition

The HIM study — which is often cited in marketing contexts — found approximately 39% of men aged 45 and older presenting to primary care offices had low testosterone on biochemical criteria alone. When the requirement for associated symptoms is added, this number falls substantially. The AUA guideline explicitly moved from "hypogonadism" to "testosterone deficiency" specifically to reinforce that the condition requires both low levels AND symptoms — not simply a lab value.[1]

Symptoms: Which Ones Point Specifically to Low Testosterone

The clinical challenge with testosterone deficiency symptoms is their non-specificity. Fatigue, poor concentration, low mood, and reduced exercise capacity can reflect dozens of conditions — including poor sleep, thyroid dysfunction, depression, anaemia, and metabolic syndrome — all of which are more common than testosterone deficiency. Understanding which symptoms are specific to testosterone versus which are non-specific is essential for avoiding over-diagnosis.

Specific Indicators
Most strongly linked to testosterone deficiency
  • Reduced sexual desire / low libido
  • Reduced or absent morning / nocturnal erections
  • Erectile dysfunction (hormonally driven component)
  • Reduced testicular volume
  • Reduced facial or body hair growth
  • Breast tissue tenderness or gynecomastia
  • Hot flashes or sweats (less common; can occur)
  • Very small testes or absence of secondary sexual characteristics (more specific to congenital causes)
The 5th ICSM 2024 specifically identified decreased spontaneous erections and low libido as the most prevalent and diagnostically specific clinical symptoms — particularly when all three sexual symptoms are present together.
Non-Specific — Many Possible Causes
Cannot reliably diagnose testosterone deficiency alone
  • Persistent fatigue and low energy
  • Depressed mood, irritability, low motivation
  • Difficulty concentrating / brain fog
  • Poor sleep quality
  • Reduced muscle mass and strength
  • Increased body fat (especially midsection)
  • Reduced exercise tolerance
  • Mild unexplained anaemia
These symptoms overlap with thyroid dysfunction, sleep apnoea, metabolic syndrome, depression, vitamin deficiencies, and simply ageing. They warrant full investigation — not assumption of testosterone deficiency as the cause.

Causes: Understanding What Type of Low Testosterone You Have

Not all low testosterone has the same cause — and the cause determines both the likelihood of natural recovery and the most appropriate treatment. The two primary categories (primary and secondary hypogonadism) are defined by where in the HPG axis the problem originates.

Primary Hypogonadism
The testes fail to produce adequate testosterone despite normal or elevated pituitary signalling. LH and FSH are high (the pituitary is "shouting" at testes that can't respond). This is structural — SERMs won't restore testosterone as the problem is downstream.
  • Klinefelter syndrome (47,XXY) — most common congenital cause
  • Testicular trauma, torsion, or surgical removal
  • Chemotherapy or testicular radiation
  • Mumps orchitis
  • Autoimmune testicular failure
  • Varicocele (modest effect)
TRT is typically the appropriate treatment for primary hypogonadism — the HPG axis cannot be "stimulated" because the testes are functionally limited.
Secondary Hypogonadism
The testes are capable of producing testosterone but are not receiving adequate pituitary stimulation. LH and FSH are low or inappropriately normal. The testes are functional — this is where lifestyle optimisation and SERMs can work.
  • Obesity / metabolic syndrome (most common reversible cause)
  • Obstructive sleep apnoea
  • Opioid medications (major, often missed cause)
  • Prolactinoma (benign pituitary tumour)
  • Chronic glucocorticoid use (prednisone, etc.)
  • Haemochromatosis (iron overload)
  • Pituitary radiation or surgery
  • Kallmann syndrome (congenital)
Secondary hypogonadism is the most common type in clinical practice. Many cases are reversible with lifestyle change. SERMs and hCG are appropriate here when fertility is a concern.

The Reversible Causes — Address These Before TRT

✓ Conditions Where Testosterone Can Recover Without TRT

  • Obesity: Excess body fat produces aromatase that converts testosterone to estrogen. Weight loss — even modest amounts — raises testosterone substantially. Multiple meta-analyses confirm low-calorie diet + exercise raises testosterone in a weight-loss-dependent manner, including in older men.
  • Obstructive sleep apnoea (OSA): OSA significantly suppresses testosterone production during the disrupted sleep cycles it causes. CPAP treatment consistently raises testosterone without any hormone therapy. OSA is dramatically under-diagnosed in men with low testosterone symptoms.
  • Opioid medications: Opioids suppress the HPG axis — this is one of the most potent and least-discussed causes of secondary hypogonadism. Any man on opioid pain medications who presents with low testosterone symptoms and low LH should have opioid-induced hypogonadism considered. Tapering opioids (where clinically possible) can restore axis function.
  • Hyperprolactinaemia: Elevated prolactin — most commonly from a pituitary prolactinoma — suppresses GnRH and LH. Treating the prolactinoma (with cabergoline) restores testosterone in most cases. Prolactin must be measured in all secondary hypogonadism workups.
  • Haemochromatosis: Iron overload deposits in the pituitary and testes, impairing both LH production and testicular function. Iron removal (therapeutic phlebotomy) can partially restore the axis. Iron studies should be included in the diagnostic workup.
  • Glucocorticoid use: Long-term corticosteroid therapy suppresses the HPG axis. If dose can be reduced or therapy weaned under specialist guidance, testosterone may recover.
📋 COVID-19 and Low Testosterone — A New Recognition The 5th ICSM 2024 consensus paper added a significant new guidance point: SARS-CoV-2 infection and long-COVID have been associated with significant testosterone decline in men, alongside more severe clinical outcomes. Men with COVID-19 or long-COVID presenting with symptoms of testosterone deficiency should be considered for serum testosterone measurement as part of their clinical evaluation — a consideration that was not in previous guidelines.[2]

How Low Testosterone Is Properly Diagnosed

The AUA / ICSM 2024 Diagnostic Process

1
Clinical symptom assessment — identify whether sexual symptoms (the most specific indicators) are present. A symptom checklist like the ADAM questionnaire can structure this. Diagnosis requires both low levels AND symptoms.
2
First morning blood test — total testosterone must be measured between 7–10am when levels are highest. A result below 300 ng/dL (approximately 10.4 nmol/L) warrants follow-up.
3
Confirmatory second morning test — a single low result is not sufficient. A second morning testosterone must confirm low levels before a diagnosis can be made. At the same blood draw: add LH, FSH, and prolactin to begin characterising the type of hypogonadism.
4
Calculate or measure free testosterone — SHBG (sex hormone binding globulin) significantly affects how much testosterone is biologically active. Men with elevated SHBG may have low free testosterone despite normal total testosterone. Free testosterone or calculated free testosterone (using SHBG and albumin) should be assessed, particularly in men with metabolic conditions or borderline total testosterone.
5
Extended workup — based on initial results: TSH, free T4 (thyroid), vitamin D, CBC, comprehensive metabolic panel, iron and ferritin (haemochromatosis), estradiol, and PSA (in men over 40 before any treatment consideration). Pituitary MRI if prolactin is elevated or if LH/FSH are very low suggesting pituitary pathology.
6
Physical examination — testicular volume assessment, signs of gynaecomastia, body hair pattern, and signs of systemic disease. Some men with hypogonadism have a normal examination; others have specific signs (small testes, reduced body hair) that aid characterisation.

The Low-Normal Zone: Where Most Complexity Lies

⚠️ The 300–450 ng/dL Problem — Where Clinical Judgment Matters Most

The majority of clinical complexity in testosterone management occurs not in men with clearly low testosterone (<200 ng/dL) but in men whose total testosterone sits in the low-normal range (roughly 300–450 ng/dL). These men are technically "within range" but may experience genuine symptoms of androgen deficiency.

Several factors can make a total testosterone in this range functionally low: high SHBG (binding more testosterone, leaving less free) from obesity, liver disease, ageing, or oral medications; a downward shift from that individual's personal normal baseline that happens to land above the lab threshold; concurrent conditions that amplify the effect of suboptimal testosterone; and individual variation in androgen receptor sensitivity.

This is where free testosterone and SHBG assessment becomes clinically critical — and where reversible causes (obesity, sleep apnoea) may bring testosterone from 380 ng/dL to 520 ng/dL with weight loss alone, resolving symptoms without any hormone therapy. For men in this zone, a structured trial of lifestyle optimisation before pharmacological intervention is both clinically appropriate and often sufficient.

The Full Spectrum of Options

Approach Best Candidate Mechanism Key Consideration
Lifestyle optimisation
First step for functional hypogonadism		 Men with reversible causes: obesity, OSA, opioids, glucocorticoids, chronic stress Removes HPG axis suppressors; restores endogenous production through natural mechanisms Most impactful and least risky option. Weight loss can raise testosterone by 100–200 ng/dL in obese men. Address before any pharmacological step.
Clomiphene / Enclomiphene
SERMs — oral, fertility-preserving		 Secondary hypogonadism + fertility goals; men who prefer oral medication; younger men with functional hypogonadism Blocks estrogen receptors at hypothalamus/pituitary → increases LH/FSH → stimulates endogenous testosterone production Preserves spermatogenesis — critical advantage over TRT. Comparable testosterone increase to testosterone gel in RCTs. Off-label use. Enclomiphene available through compounding only.
hCG
LH analogue — injectable, fertility-preserving		 Secondary hypogonadism; men desiring to preserve testicular function and fertility while treating low testosterone; adjunct to TRT Mimics LH directly → stimulates Leydig cells to produce testosterone and maintain testicular function Requires injection; may elevate estradiol requiring management. Brand Pregnyl available; compounding hCG restricted. Can be combined with SERMs or TRT.
TRT — Transdermal Gel
Most common delivery		 Confirmed hypogonadism; no current fertility goals; preference for daily non-injection administration Exogenous testosterone delivered through skin; bypasses HPG axis; suppresses spermatogenesis Daily application required; transfer risk to partners; well-studied (used in TRAVERSE). Most convenient for many patients. Suppresses fertility.
TRT — Subcutaneous Injection
Testosterone cypionate/enanthate		 Men who prefer weekly self-injection; lower cost than gels; desire stable levels Same as gel — exogenous testosterone; subcutaneous preferred over intramuscular for self-administration Weekly administration. Subcutaneous small-needle technique is well-tolerated. Produces more stable levels than biweekly dosing.
TRT — Oral Undecanoate
Jatenzo, Tlando		 Men who strongly prefer oral administration; those unable or unwilling to inject or apply gels Absorbed via lymphatic system (avoiding liver first-pass); delivers testosterone systemically Must be taken with fat-containing food for absorption. Twice daily dosing. Newer and fewer long-term data than injectable/gel TRT.
No treatment / monitoring
A legitimate clinical choice		 Men with borderline levels and mild or unclear symptoms; those with significant medical contraindications; men wanting to complete lifestyle optimisation first N/A — active surveillance Often overlooked as an option. For men with low-normal testosterone and non-specific symptoms, a structured lifestyle trial followed by reassessment at 3–6 months is clinically appropriate and may resolve the question.

The Clinical Bottom Line

Low testosterone is a real condition that meaningfully affects quality of life for many men — and it is also significantly over-diagnosed and over-treated when patients present with non-specific symptoms and borderline lab values. The most important clinical step before any treatment decision is establishing that the clinical diagnosis is valid: two confirmed morning tests below threshold AND specific symptoms. The most important second step is identifying and addressing reversible causes — particularly obesity and sleep apnoea — before committing to long-term hormone therapy. For men with true, confirmed testosterone deficiency who have addressed reversible causes, the treatment options are well-developed, safe under appropriate monitoring, and genuinely effective for the right patients.

Concerned your testosterone might be low?

Our free quiz helps you think through your situation clearly before speaking with a clinician.

Take Our Peptide Plan Quiz →

References

  1. American Urological Association. Testosterone Deficiency Guideline. Available from: https://www.auanet.org
  2. Khera M, et al. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025;13(4):548–573. Available from: https://pubmed.ncbi.nlm.nih.gov/40862363/
  3. NCBI Bookshelf (StatPearls). Male Hypogonadism. Updated February 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532933/
  4. Cleveland Clinic. Low Testosterone (Male Hypogonadism). Updated February 2026. Available from: https://my.clevelandclinic.org
  5. PMC. A practical guide to male hypogonadism in the primary care setting. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2948422/
  6. ScienceDirect. Testosterone Therapy in Adult Males with Hypogonadism. Updated to April 2025. Available from: https://www.sciencedirect.com
  7. Bhasin S, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. Available from: https://pubmed.ncbi.nlm.nih.gov/29562364/